The global engineered cell therapy market was anticipated to reach a valuation of US$ 4.2 Billion in the year 2022. With a robust CAGR of 14.7% from 2023 to 2033, this market is expected to reach US$ 4.82 Billion by 2023 and US$ 18.99 Billion by 2033.
Some of the significant factors that are responsible for propelling the global engineered cell therapy market are:
New cell types are continuously entering the engineered cell therapy industry, providing tremendous opportunities for businesses to improve their market positions. As a result, the number of businesses working on the development of cell treatments has dramatically increased during the past several years. Other key reasons impacting the expansion in the number of firms in the market are the rise in financing for cell therapy biomedical studies, the adoption of practical standards for cell therapy production, and the success of innovative products.
A decrease in the price of engineered cell treatments has also increased consumer interest. The creation of cell banking facilities and the subsequent expansion of cell production, storage, and characterization have improved the market's capacity to deal with significant volumes on a worldwide basis. The market's improved income creation over the preceding several years has been directly attributed to this.
The existence of both public and commercial financing organizations, which routinely provide approvals to projects to assist throughout all phases of clinical trials, can be linked to a rise in the number of clinical studies. Most late-stage initiatives in Europe receive funding from grants from the EU. For instance, Achilles Therapeutics announced in July 2022 that it had received the "Horizon Europe" grant, worth USD 4.2 million. It is the main financing program for research and innovation in the EU. The production of tailored therapies will advance thanks to this support. Such developments are anticipated to open up new avenues for this market from 2023 to 2033.
In the upcoming years, the market is anticipated to increase significantly in the domain of musculoskeletal problems. Much research is being done to develop technologies that make it easier for injured musculoskeletal tissues to regenerate or be repaired. Diverse research teams examine the therapeutically relevant cell types that are used in treatments for the degeneration of musculoskeletal tissues and use engineered or native skeletal progenitor cells to stimulate tissue repair and revitalize musculoskeletal tissues.
With a 52% market share in 2022, North America had the highest share of the engineered cell therapy market. This is a result of regional pharmaceutical industry titans and academic institutes collaborating on research projects. With several partnerships, there are new developments in the area. For instance, Immatics and Bristol Myers Squibb worked together to create the Gamma Delta Allogeneic Cell Therapy Programme in June 2022. Immatics as well as Bristol Myers will jointly develop two projects that Bristol Myers Squibb will own, and both companies have the potential to develop a total of four more treatments.
By pushing it to physicians for use in transplant surgeries, leading players in the industry are launching a variety of campaigns to grow their client base. Also, to improve their market position, these businesses are launching new products and engaging in partnerships, collaborations, mergers, and acquisitions. For instance, 2seventy Bio and Regeneron signed an extended translational partnership agreement in January 2023 to develop novel cell therapy-based drug combinations for solid malignancies. Also, in September 2021, Adaptimmune Therapeutics plc announced a partnership with Genentech for the creation and promotion of allogeneic treatments that would be used to treat a variety of oncology-related illnesses. These developments are expected to propel the demand in this global market during the forecast period.
| Data Point | Key Statistics |
|---|---|
| Expected Market value in 2023 | US$ 4.82 Billion |
| Expected Market value in 2033 | US$ 18.99 Billion |
| Growth Rate (2023 to 2033) | 14.7% from 2023 to 2033 |
Cellular engineering appertains the proposition and strategies of engineering related to the defects of cell and biological science of each a basic and applied nature. However, biomedical engineering has shifted from the tissue & organ level to the sub-cellular & cellular level, cellular engineering has surged as a replacement space. Moreover, the foundation of this process includes the cell culture technology that is the flexibility to grow living cells inside the artificial surroundings of a laboratory.
Additionally, Cellular engineering involves the role of engineering in cell biology analysis and for the creation of a product that utilizes living cells, i.e. Tissue & bioprocess engineering. In this process, the living cells are utilized for the manufacturing of an organic chemistry product, for example, recombinant deoxyribonucleic acid technology.
Biopharmaceutical manufacturers are at the vanguard of the human reaction to the COVID-19. A variety of principal biotech corporations are inside the middle of a race to research the Sars-Cov-2 genome and put together a feasible vaccine for the equal. Moreover, the biotech companies are examining the SARs-Cov-2 at an exceptional price and a worthwhile amount of price range is being put forward into Research & Development.
With various drugs trials, the private and non-private sectors are predicted to work together for the foreseeable length, until a vaccine is advanced for coronavirus. Hence, the competition amongst the companies are increasing and thus the demand for these products are propelling for the preparation of medicines.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Tissue engineering has helped to overcome the damaged tissues. There are end number of patients globally waiting for the organ transplantation. Meanwhile, Owing to the limited organ donors’ availability, organ transplantation has become too difficult. Engineered cell therapy is managing the gap with this aspect.
Rising research investments for cell therapy and tissue engineering is aiding to fuel the engineered cell therapy market growth. Engineered cell therapy is advantageous and overcoming the varied barriers for providing treatment to the patients. However, the method is very expensive, thus it is posing as the threat to the growth of the engineered cell therapy market.
The cardiovascular segment is estimated to boosts the market growth due to the increasing cases of cardiovascular diseases worldwide. Additionally, the major players are associated with the development of engineered cell therapies to restore and re-vascularize the deface heart tissues.
Moreover, the biologics, gene therapy, and macromolecules are being observed to incite the restoration of damaged heart cells. Additionally, the diagnostic centers segment held the largest share owing to the rising research and development activities and the utilization of engineered cell therapy in molecular diagnostics. While the biologically derived materials have a major role in the development of cellular engineering therapy that increases the restorative potential to human tissues to restore the normal body function, in the case of damage.
Principal Consultant
Geographically, the engineered cell therapy market is segregated into seven regions viz. Asia Pacific, North America & Latin America, Eastern Europe Western Europe, Japan, & the Middle East and Africa. North America is projected to ascendant the engineered cell therapy market followed by Asia Pacific & Europe. North America has a major market share due to the awareness for engineered cell therapy in the geriatric populace.
Additionally, advanced technology for investigation and treatment of chronic diseases, accessibility of private and government funding, and high healthcare spending are propelling the engineered cell therapy market.
The key participants operating in the global engineered cell therapy market identified across the value chain include
These organizations are involved in strategic alliances, deals, and development of newer products to maintain their market share.
Fast headways and a solid pipeline of regenerative medication are foreseen to give compelling answers for constant conditions. A few organizations in developing markets are endeavouring to benefit from the undiscovered market potential with a solid spotlight on R&D.
For example, RepliCel is putting resources into various regenerative medication items. Starting at 2019, the company’s few items including RCH-01, RCS-01, RCT-01 were in the advancement stage and While the dermal injector gadget i.e. RCI-02 is in pre-commercialization creation and testing stage.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global engineered cell therapy market has been segregated based on product type, indication and geography.
Healthcare
December 2022
REP-GB-1655
250 pages
Explore Healthcare Insights
View Reports
Engineered Cell Therapy Market
